Cowen analyst Ritu Baral lowered the firm’s price target on InMed Pharmaceuticals to $45 from $53 and keeps an Outperform rating on the shares. The analyst updated his model to reflect guidance and adjusted his target and forward estimates for growth and WW revenues while also noting the ASPEN study remains on track while brenso Ph2 PK/PD was clean.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INM:
- InMed Provides Business Update and Milestones for 2023
- Sell these stocks now, proven algorithm says
- InMed Announces Results of 2022 Annual General Meeting
- InMed Pharmaceuticals engages Marcum LLP as auditor after KPMG resigns
- InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
